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Assessing Amyotrophic Lateral Sclerosis prevalence in Norway from 2009 
to 2015 from compulsory nationwide health registers 
 
Objective:  In Norway diagnoses from specialist health care visits, drug prescriptions, 
and causes of deaths are registered in compulsory health registers. We aimed to 
determine amyotrophic lateral sclerosis (ALS) prevalence from 2009 to 2015 by 
combining these registers. Methods: We validated the Norwegian Patient Registry 
(NPR) through hospital files, and linked it with the Norwegian Cause of Death Registry 
and the Norwegian Prescription Database. Poisson regression models were fitted for 
estimating gender ratios, time trends and possible interactions. Similar models were 
used for mortality data subtracted from the dataset. Results: Eleven percent of patients 
with at least one ALS-related entry in NPR did not have ALS. ALS prevalence could 
nevertheless be reliably estimated through ascertaining cases identified in two separate 
registers, or with at least two entries in NPR with first entry within four years prior to 
prevalence date. ALS prevalence remained stable, and was 7.6/100000 (95 % CI 6.9-
8.4) at 31
st
 December 2015. Mean male: female ratio was higher for prevalence (1.8; 
95% CI 1.6-2.0) than for mortality (1.5; 95% CI 1.2-1.8) (p=0.04). There were also 
significant regional differences in prevalence (p<0.01) but not in mortality.  
Conclusions: Norwegian compulsory health registers provide reliable tools for ALS 
surveillance, and suggest gender and regional differences in survival after diagnosis.    
 




Amyotrophic lateral sclerosis (ALS) mortality is increasing within the Norwegian aging 
population (1). Whereas no nationwide prevalence study has been conducted in Norway, 
studies based solely on hospital records in two single counties found prevalence rates of 
3.67/100,000 on 31
st
 December 1988 (2) and 4.06/100,000 on 31
st
 December 2007 (3).  
In Europe,  reported ALS prevalence ranges from 1.1/100,000 in former Yugoslavia (4) 
to 10.3/100,000 in the Netherlands (5). Methods of data collection differ across studies. 
Combining multiple data sources is generally considered the best strategy (6, 7). Whilst 
dedicated ALS-register data have the advantage of case ascertainment of high validity, 
population based prevalence estimates from national compulsory health registers can provide 
nationwide data in a clinically relevant setting. 
Norway has a relatively stable population and equal access to health care. There are 
public hospitals with neurological services in all counties where ALS patients are diagnosed 
and typically followed every third month, and medical care including prescription drugs are 
provided free of charge above a yearly threshold of 237 Euro (8). All drug prescriptions, 
diagnoses from public and private specialist health care, and causes of deaths are registered in 
compulsory health registers. The registers have been operating for several years and can be 
linked through a unique identification number, allowing prevalence estimates of potentially 
high accuracy (9). The aim of this study was to combine these registers to determine the 
prevalence of ALS in Norway from 2009 to 2015.  
Materials and Methods 
Data were extracted from the Norwegian Patient Registry (NPR), the Norwegian Prescription 
Database (NorPD), the Norwegian Cause of Death Registry (NCoDR) and population data 
from Statistics Norway in august 2016, and linked through unique person identification 
numbers. For the purpose of including Norwegian citizens only we excluded individuals 
without information on residency, and to avoid obvious misdiagnoses we also excluded cases 
born after 1990. 
Norwegian Patient Registry  
NPR is an administrative health register for all in –and outpatient admissions to Norwegian 
hospitals and private practice specialists with public reimbursement. Data on individual 
patients are available from 1
st
 March 2007. Dates of admission and discharge, diagnoses 
according to the International Classification of Diseases 10
th
 revision (ICD 10), and 
surgical/medical procedures are registered electronically for each admission/consultation.  We 
collected data for all entries with ICD 10 = G12.2 from 1
st
 January 2008 to 31
st
 December 
2015, including gender, age (10 year birth cohorts), residence (health region), year of first 
registration, whether the patient was alive on each prevalence day (Statistics Norway), and 
whether each individual had one single or more entries in the register. Differentiation between 
sporadic ALS, familial ALS, and primary lateral sclerosis through a five-digit coding level of 
G12.2 in ICD10 was not possible until 2017, and was therefore not performed in this study.  
Norwegian Prescription Database  
NorPD contains a complete electronic listing of all prescription drugs dispensed by 
Norwegian pharmacies since 2004. Riluzole is only used for ALS, and is offered free of 
charge to almost all ALS-patients. We collected data on all riluzole dispenses (Anatomical 
Therapeutic Classification  code N07X X02) from 2004 onwards, including gender, age (1 
year birth cohorts), year of dispense(s) and year of death (Statistics Norway). 
Norwegian Cause of Death Registry 
NCoDR collects and processes all death certificates (DCs), and provides digitalized data for 
the direct, contributing and underlying cause of all deaths in Norway since 1951, from 1996 
using ICD 10. We collected data on gender, age at death (1 year bins) and year of death for all 
those deceased between 31
st
 December 2008 and 31
st
 December 2015 encoded ICD 10 = 
G12.2 in their DC. 
Mortality data for ALS are generally considered reliable (10). In line with this, we 
have earlier shown that 96 % of deceased patients correctly diagnosed with ALS were 
retrieved in NCoDR (1).  
Hospital files 
Hospital files from Akershus University Hospital and Haukeland University Hospital were 
used to validate ALS diagnoses given at hospitals. Together, these hospitals provide 
neurological services to approximately 20% of the population in Norway. Two authors (ON 
and OBT) reviewed the hospital files of all patients registered with ICD10=G12.2 in an 
outpatient visit or inpatient admission at any department from 1
st
 January 2008 to 31
st
 
December 2015. The patient was considered misclassified if not fulfilling the Awaji criteria 
for possible, probable or definite ALS (11). The identity of all deceased patients identified in 
this process was sent to NPR to assess the completeness of the registry. We also reviewed 
hospital files of patients coded as G12.8 and G12.9 (unspecified/other spinal muscular 
atrophies) to evaluate the specificity of these diagnoses and how often these were reclassified 
as ALS. Ultimately, to assess whether the diagnostic accuracy in the two university hospitals 
were representative for the country as a whole, we asked NPR to quantify the number of 
individuals first coded as G12.8/G12.9 and later as G12.2. 
Case definitions and Analyses 
For our main prevalence estimates we used the following ALS case definition; 
 Alive at prevalence date, minimum one entry in at least two of three registers (riluzole 
dispense in NorPD, G12.2 in NPR/NCoDR; at least one prior to prevalence date). 
or 
 Alive at prevalence date, minimum two G12.2 entries in NPR, at least one of these 
prior to prevalence date, and first entry no more than four years prior to prevalence 
date. 
 
Prevalence was calculated as the number of patients satisfying our case definition every 31
st
 
December from 2009 until 2015, divided by the corresponding total population in Norway. 
Ninety-five % confidence intervals (CI) for proportions were calculated by the exact method. 
Poisson regression with robust variance (12) was fitted for prevalence ratios, time trends and 
possible interactions. Independent variables in the model included gender, age as first and 
second degree term, prevalence year, and was extended with health regions and interaction 
terms for regional rate ratios and annual change in national prevalence or gender ratio, 
respectively. Similar models were fitted for mortality data only, enabling comparison of rate 
ratios between prevalence and mortality data. Wald test was used to determine whether there 
were differences in prevalence between health regions, and in addition regional rates were 
internally standardized by the direct method for comparison. A continuous age variable was 
constructed by subtracting median birth year from prevalence year, and from this we 
calculated mean age. A linear regression model with gender, prevalence year, interaction 
between the two and mean age in the total population was fitted for analyses of mean age 
trends and differences. We used chi square to test for gender differences in riluzole use. The 
statistical software Stata (Version 14.2, StataCorp LP, TX, USA) was used for all analyses. 
Results 
Validation 
We first tested the accuracy of ALS diagnoses by reviewing the hospital files at Akershus 
University Hospital and Haukeland University Hospital for all entries coded G12.2 from 1
st
 
January 2008 to 31
st
 December 2015. Out of a total number of 375 patients 42 (11 %) were 
misclassified. Of these, only 12 (3 %) were coded with G12.2 twice or more. Misclassified 
cases generally had diseases with longer expected survival such as congenital motor neuron 
disease, polyneuropathy and post-polio syndrome. We next tested whether patients diagnosed 
with G12.2 were retrieved in NPR. Out of a total 277 unique and deceased patients diagnosed 
with G12.2 at Akershus University Hospital or Haukeland University Hospital from 1
st
 
January 2008 to 31
st
 December 2015, 273 (98,6 %) patients were retrieved in the registry. We 
next reviewed all 70 hospital files from patients coded as G12.8 or G12.9 in the same period. 
Ten of these fulfilled the Awaji criteria for ALS, and another four later developed ALS. 
Twelve out of these 14 cases were however coded twice or more as G12.2 during the study 
period, and therefore not missed in the study. At a country level, a total of 63 individuals 
initially coded as G12.8 or G12.9 were later coded twice as G12.2 in NPR.  
The consistency between register entries are displayed in supplementary Table 1. 
Because of legal constraints and privacy concerns, direct validation of NorPD is difficult. 
However, of the 1216 cases with at least two G12.2 entries in NPR (constricted as in the main 
case definition), 944 (78 %) were retrieved with ever riluzole dispense in NorPD. For NCoDR, 
the corresponding proportion was 687 out of 971 (71 %).  
ALS prevalence  
We identified 1720 eligible individuals in NPR from January 1
st
 2008, 955 in NCoDR from 
January 1
st
 2009 and 1556 in NorPD from January 1
st
 2004.  Using the main case definition, 
ALS prevalence in Norway ranged from 6.9/100,000 (95 % CI 6.2-7.7) on 31
st
 December 
2009 to 7.7/100,000 (95 % CI 6.5-7.9) on 31
st
 December 2011 (Figure 1 and Table 1). There 
were no longitudinal trends (p=0.98). The male: female gender ratio ranged from 1.6 to 2.0 
(Table 1), also without any changes throughout the study period. Females tended to be older 
than males (1.6 years; p=0.14). Longitudinally, mean age increased for females, different 
from no change among males (p=0.01). Of the 882 male cases identified through either 
NCoDR or within the NPR main case definition subgroup, 73 % had ever dispensed riluzole. 
Amongst the 637 females, the corresponding proportion was 68% (p=0.02). Amongst those 
found in NCoDR, mortality rates were calculated from 2009 to 2015. Within this period, there 
was no significant trend in mortality rates. The mean male: female ratio was 1.5 (95 % CI 1.2-
1.8) for mortality and 1.8 (95 % CI 1.6-2.0) for prevalence (p=0.04). 
(Table 1 near here) 
Prevalence estimates for possible alternative case definitions are also shown in Figure 
1. Using the most conservative definition requiring at least one entry in two separate registers, 
prevalence ranged from 6.0 (95 % CI 5.4-6.8) to 6.3/100,000 (95 % CI 5.6-7.0). This is most 
likely an underestimate, as a substantial proportion of patients are either not yet deceased or 
do not use riluzole, and consequently not registered in NorPD or NCoDR. Using the most 
liberal case definition allowing for cases only registered once  in NPR, estimated prevalence 
increased by 5.2 % (p<0.01) per year and ended at 11.1/100,000 (95 % CI 10.3-12.1). This 
likely reflects that 11 % of patients reported with G12.2 to NPR did not have ALS, and that 
these generally live longer than those with ALS and therefore accumulate in the registry over 
time. Requiring minimum two entries in NPR would reduce this error as only 3 % were 
misclassified twice, but without further censoring their contribution would also increase over 
time. In possible agreement with this notion, the prevalence estimate based on this case 
definition increased by 2.7 % (p=0.16) per year and ended at 8.7/100,000 (95 % CI 7.9-9.6).  
(Figure 1 near here) 
Contribution from different registers 
Figure 2 displays how the registers contributed to the prevalence estimates based on our main 
case definition throughout the study period. As expected, in the first part of the period most 
patients were registered in both NPR and NCoDR, whereas NorPD became increasingly 
important at the end of the study. As our latest prevalence date coincided with NCoDRs final 
recording, no cases could be ascertained from NCoDR at this date. The proportion of cases 
ascertained exclusively through NPR increased throughout the study period, compensating the 
declining contribution from NCoDR, and also reducing the proportion of those depending on 
riluzole dispense. 
(Figure 2 near here) 
Regional, gender and age distribution 
There were significant differences in prevalence between the four health regions (p<0.01) 
(Table 2). A post hoc analysis showed that prevalence rates were 19 % greater in Region West 
(p<0.01) compared to South-East, with 20 % more men (p=0.07). Region Middle and North 
did not differ significantly from South-East with regards to prevalence rates or gender ratio. 
No geographical differences in rates or gender ratios were seen when analysing mortality data 
(NCoDR) separately.  
(Table 2 near here) 
Figure 3 displays age distribution by gender. The age group with highest prevalence amongst 
both genders was 70-79 years. There were more males than females in every age group. 
Prevalence dropped amongst the highest age groups in both genders. 
(Figure 3 near here) 
Discussion 
By combining three compulsory health registers, we found a stable prevalence of ALS in 
Norway from ultimo 2009 to ultimo 2015. The estimated prevalence was almost twice as high 
as previously reported in single counties (2, 3), with significant regional and gender 
inequalities. ALS prevalence estimated in other European studies conducted retrospectively 
display great variability (4-11/100,000) (13-20) . Reports based on European prospective 
population based ALS-registers are more uniform (7-9/100,000) (21) and concur with our 
estimates. The difference in ALS prevalence between the present and previous studies 
exceeds the modest increase in incidence suggested by mortality (1). This discrepancy may be 
due to methodological differences, as previous studies were based solely on hospital files (2, 
3). Although prevalence did not change during our limited observation period, we cannot 
exclude that also increased survival has contributed to increased prevalence. No disease 
modifying agent has been introduced in Norway since riluzole in 1996 (22). The use of 
riluzole did not change during the study period (23). The use of mechanical ventilation 
amongst ALS-patients is however increasing (24, 25), and has a substantial effect on survival 
(26). Increased awareness and changes in diagnostic practice, including genetic testing, could 
also impact prevalence estimates (27).  In Norway there seems to be a clustering of familial 
ALS with the SOD1 H46R mutation (28, 29). These patients generally have long survival (30), 
and may therefore have substantial impact on prevalence rates despite being relatively few.  
The male: female ratio for mortality in our study (1.5) was consistent with that 
reported previously for incidence rate (1.4) in Europe (31). The gender ratio for prevalence 
(1.8) was however higher, suggesting that males live longer with the diagnosis. Similar 
gender differences for ALS survival have been reported previously (32). Independent factors 
such as young age, spinal onset, the diagnosis of “possible ALS” and symptoms having 
started more than 12 months prior to diagnosis predict longer survival (32). Of these, we were 
only able to register age, crudely derived from birth cohorts and prevalence year. Although 
generally younger males support this coherence, gender differences in adopting therapeutic 
measures and life-sustaining interventions such as riluzole, percutaneous gastrostomy, and 
mechanical ventilation also could influence survival. Indeed, we found that more men than 
women had dispensed riluzole. Moreover, data from the Norwegian Mechanical Ventilation 
Register has shown that more men (70%) than women (30%) used long term mechanical 
ventilation (25). For either of the treatments, our data cannot separate if the observed gender 
difference is due to patients’ or physicians’ preferences. It is possible that distinctive gender 
roles make females more inclined to accept either their own disease course, or to accept the 
nursing role for their sick spouses (33). 
We found differences in ALS prevalence between health regions. Similar geographical 
differences were not found for mortality. Although the latter analysis was performed post hoc 
and the discrepancy in regional prevalence versus mortality is uncertain, it may indicate 
differences in survival. Environmental factors such as smoking and low socioeconomic status 
have been linked to short survival (34), but we are not aware of such regional differences in 
Norway. Whereas the use of riluzole seems to be very similar across Norway (23), an earlier 
report revealed regional differences in adopting long term mechanical ventilation (35). The 
regional differences in the use of mechanical ventilation did however not correspond to those 
observed for ALS prevalence, and can therefore not explain these. It should be noted that even 
small differences in the timing of the diagnostic workup could have substantial impact on 
prevalence rates, and that the health region with highest ALS prevalence was the first to 
invent a multidisciplinary ALS team in Norway (36).  
There are several pitfalls when using automated hospital discharge and prescription 
data in epidemiological studies, including errors due to misclassification (37). When 
evaluating hospital files we found that 11 % of those who were encoded G12.2 once, and 3% 
of those encoded G12.2 twice, did not have ALS. As these misclassified cases generally had 
diseases with longer life expectancy than in ALS they would accumulate in NPR over time. 
Requiring entry in two separate registers would prevent this. However, as a substantial 
proportion of our patients were either not deceased (increasingly towards the end of our study 
period), or in line with previous reports had not dispensed riluzole (13, 38), it would 
underestimate prevalence. To avoid both these pitfalls, we decided that to be included solely 
based on two or more entries in NPR, the first entry had to be no more than four years prior to 
prevalence date.  This criterion does not allow cases misclassified as ALS to accumulate over 
time, and thereby restricts the overestimation to approximately 3% throughout the study 
period. Because the vast majority of ALS patients will meet a specialist more than once and 
does not survive beyond four years, it would nevertheless catch most living cases not using 
riluzole, who would otherwise be lost. Our main case definition therefore included patients 
either fulfilling this criterion, or registered in two separate registers.  
There is a possibility that patients with ALS were not given correct ICD-code 
(negative misclassification) both in NPR and NCoDR, leading to under ascertainment. From 
our hospital records, such cases were however very few. It is however possible that we have 
missed some ALS patients with long survival and rare visits to neurologists, particularly if 
these do not use riluzole. Some patients with H46R SOD1 mutation might fall into this 
category (29). Also some ALS patients living in nursing homes could be missed, as severe 
disability might prevent them from seeing a specialist regularly, and NorPD only collects data 
from drugs dispensed in pharmacies.   
Although each register is compulsory, neither of them was redundant in this study. 
Because the first prevalence date was set only two years after NPRs first recording, some 
prevalent cases could have been missed in this registry at this date. NCoDR and NorPD could 
however catch these cases.  NCoDR would obviously gradually lose relevance in recent time, 
and it is also necessary to combine this registry with other data sources to identify when each 
case became incident.  Although the use of several registers allows verification of the 
diagnosis and the incidence year, the changing contribution from each register during the 
study period could potentially disguise a true change in ALS prevalence. Furthermore, the 
validation of our main case definition relies much on hospital files at two university hospitals. 
Although neurological services are rather homogenous throughout Norway, we cannot rule 
out that the diagnostic accuracy at these hospitals do not represent the country as a whole. Our 
evaluation of reclassified cases however crudely indicates such proportionality. 
In conclusion, combining three compulsory health registers in Norway reveals that 
ALS prevalence remained stable from 2009 to the end of 2015, at a level consistent to other 
European countries and considerably higher than reported in previous studies based solely on 
hospital records. Our data also reveal differences in prevalence between genders and regions 
that are not likely explained by differences in incidence. It is known that males are more 
likely to use mechanical ventilation, and we here show that males also are more likely to use 
riluzole. These inequalities need to be further explored.  
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